On ‘International Mount Everest Day’ (29th May) ‘The Art Maze’, by Curator Marcus Schaefer, Unveils Artist Sacha Jafri’s Latest Masterpiece as a First Time Ever Event at Mount Everest
31.5.2022 09:00:00 EEST | Business Wire | Press release
‘The Art Maze’ World Tour, in partnership with UNESCO, is an unpresented collection of 50 UNESCO World Heritage Sites, created by celebrated Artist, Sacha Jafri, in celebration of UNESCO World Heritage Site’s 50th year anniversary and The Next 50, a year-long UNESCO campaign promoting interdisciplinary reflection on the future of the World’s Heritage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005345/en/
Jafri's Everest Painting Unveiled (Photo: AETOSWire)
Jafri, awarded by the UN for his humanitarian work raising over $140 million for charitable causes, is unveiling his ‘Sagarmatha National Park - Mount Everest’ painting, a spectacular 380cmx160cm three-canvas Triptych piece. With this project Jafri aims to reconnect humanity to our cultural heritage, our ancestral past and the beauty that surrounds us within our natural world, as well as shine a light on the important conversations and actions so desperately needed for the future of our world, in the areas of equality, sustainability & climate change.
Sacha Jafri, Artist & Philanthropist: “It is such an honour for me to partner with ‘The Art Maze’ and UNESCO using the power of art to reconnect with humanity in space and on earth.”
Marcus Schaefer, Art Visionary & Curator: “Feeling such a strong connection to this great country, we are so excited to unveil Sacha’s latest painting with the people of Nepal at the majestic Mount Everest.”
Michael Croft, Head of Office and Representative to Nepal at UNESCO: “As we listen to communities from the mountain regions and hear their perspective on tackling the dual challenges of climate change and sustainable tourism, we are at once motivated - and better informed - how best to fashion our own actions for change.”
UNESCO’s partnership with ‘The Art Maze’ and Sacha Jafri reinforces its mission of promoting inclusive, interdisciplinary dialogues related to climate change, heritage conservation, sustainable tourism, and the challenges these sites face in the context of climate change. In Nepal, UNESCO is working to bring together mountain community leaders as part of The Next 50 dialogues.
Raza Beig, Chairman of BoredPuma: “So excited to be able to announce my purchase of this monumental painting - I now own a piece of a living Indian master, Sacha Jafri, but also, the artistic expression of the world’s largest natural beauty - Mount Everest.”
In honour of this cause, Jafri is producing a signature print collection for art lovers who are keen to own a piece of his humanitarian journey. They can be found at: https://www.collection.theartmaze.com/
‘The Art Maze’ visits 18 countries across six continents of the world 2022-2024 with the next stop in Paris, September 2022, at UNESCO’s Headquarters commemorating the organisation’s 50th anniversary with all 50 of Jafri’s paintings on display.
Follow ‘The Art Maze’
WEBSITE:
www.theartmaze.com
@sachajafri @the.artmaze
Download Images & Films
HERE
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005345/en/
Contact information
Leidar
Lejo Johnny
Lejo.johnny@leidar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom